Vaxart Up on Pre-Clinical Data on Coronavirus Vaccine Candidates
Vaxart's (VXRT) several COVID-19 vaccine candidates generate immune responses in pre-clinical studies. Stock rises.
Chart
Attachments
Strong buy
Análisis técnico de Vaxart (VXRT) - Investing.com
Acceda al análisis técnico de Vaxart, un resumen de las señales de compra/venta de los principales indicadores para las acciones de Vaxart (VXRT).
m.es.investing.com
SOUTH SAN FRANCISCO, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it has obtained positive pre-clinical results for its COVID-19 vaccine candidates, with several of the vaccine candidates generating immune responses in all tested animals after a single dose.
“These pre-clinical results confirm that all constructs are immunogenic as measured by IgG antibodies in serum, and we observed a robust boosting effect after the second dose.” said Sean Tucker, Ph.D., chief scientific officer of Vaxart. “This latest data set will help to select the lead candidate for manufacturing, and we remain on track to start a first phase 1 study in the second half of this year.”
In January 2020, Vaxart initiated a program to develop a COVID-19 vaccine based on its VAASTTM oral vaccines platform. The Company is currently evaluating multiple vaccine candidates in its preclinical models. In this second round of preclinical testing, all animals received two doses of the Vaxart vaccines, two weeks apart. Antibody responses in all vaccinated groups were statistically significant compared to the untreated controls. Vaxart plans to select one or more vaccine candidates for cGMP manufacturing and clinical testing based on the magnitude and the breadth of the immune response.
“Our oral vaccines have been shown to protect against respiratory infection based on mucosal immunity, the first line of defense for such infections, as recently published in the Lancet Infectious Diseases,” said Wouter Latour, MD, chief executive officer of Vaxart Inc. “This could be important for an effective vaccine that protects the global population from COVID-19. In addition, the Vaxart vaccine would be administered orally using a room temperature-stable tablet, an enormous logistical advantage over injectables in large vaccination campaigns.”
About Vaxart
Vaxart is a clinical-stage biotechnology company primarily focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart’s vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may also be useful for the treatment of chronic viral infections and cancer. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (“RSV”), as well as a therapeutic vaccine for human papillomavirus (“HPV”). For more information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from pre-clinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “plan” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates and clinical results and trial data (including plans with respect to the COVID-19 vaccine product candidates); expectations relating to Vaxart’s relationship with Emergent, including Emergent’s ability to produce bulk cGMP vaccine and the timing thereof; and Vaxart’s expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV, as well as coronaviruses such as SARS, MERS and SARS CoV-2. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s control, including the recent outbreak of COVID-19; that Vaxart may not be able to obtain, maintain and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.
Contact
Brant Biehn
Vaxart Inc
650 550 3500
investors.vaxart.com
“These pre-clinical results confirm that all constructs are immunogenic as measured by IgG antibodies in serum, and we observed a robust boosting effect after the second dose.” said Sean Tucker, Ph.D., chief scientific officer of Vaxart. “This latest data set will help to select the lead candidate for manufacturing, and we remain on track to start a first phase 1 study in the second half of this year.”
In January 2020, Vaxart initiated a program to develop a COVID-19 vaccine based on its VAASTTM oral vaccines platform. The Company is currently evaluating multiple vaccine candidates in its preclinical models. In this second round of preclinical testing, all animals received two doses of the Vaxart vaccines, two weeks apart. Antibody responses in all vaccinated groups were statistically significant compared to the untreated controls. Vaxart plans to select one or more vaccine candidates for cGMP manufacturing and clinical testing based on the magnitude and the breadth of the immune response.
“Our oral vaccines have been shown to protect against respiratory infection based on mucosal immunity, the first line of defense for such infections, as recently published in the Lancet Infectious Diseases,” said Wouter Latour, MD, chief executive officer of Vaxart Inc. “This could be important for an effective vaccine that protects the global population from COVID-19. In addition, the Vaxart vaccine would be administered orally using a room temperature-stable tablet, an enormous logistical advantage over injectables in large vaccination campaigns.”
About Vaxart
Vaxart is a clinical-stage biotechnology company primarily focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart’s vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may also be useful for the treatment of chronic viral infections and cancer. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (“RSV”), as well as a therapeutic vaccine for human papillomavirus (“HPV”). For more information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from pre-clinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “plan” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates and clinical results and trial data (including plans with respect to the COVID-19 vaccine product candidates); expectations relating to Vaxart’s relationship with Emergent, including Emergent’s ability to produce bulk cGMP vaccine and the timing thereof; and Vaxart’s expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV, as well as coronaviruses such as SARS, MERS and SARS CoV-2. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s control, including the recent outbreak of COVID-19; that Vaxart may not be able to obtain, maintain and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.
Contact
Brant Biehn
Vaxart Inc
650 550 3500
Vaxart, Inc. –Vaxart Announces Additional Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program
The Investor Relations website contains information about Vaxart, Inc.'s business for stockholders, potential investors, and financial analysts.
Stock Picks, Stock Market Investing
Vaxart Shows Strong Progress in Its COVID-19 Program; 5-Star Analyst Boosts Price Target
https://finance.yahoo.com/news/covid-19 ... 14673.html
https://finance.yahoo.com/news/covid-19 ... 14673.html
Vaxart Announces First Quarter 2020 Financial Results and Provides Corporate Update
finance.yahoo.com
Vaxart Announces First Quarter 2020 Financial Results and Provides Corporate Update
“In January we pivoted to COVID-19, and we are now on track to start a first Phase 1 study in the second half of this year with our oral tablet vaccine,” said Wouter Latour, MD, chief executive officer of Vaxart. “We are developing a state-of-the-art gene-based vaccine utilizing our proprietary...
EXCLUSIVE: Coronavirus vaccine taken by tablet instead of injection is about to go into human trials – and scientist in charge says he believes there WILL be a vaccine by next year
www.dailymail.co.uk
COVID-19 vaccine taken by tablet is about to go to human trials
Immunologist Dr. Sean Tucker is currently trialing several different COVID-19 vaccine candidates at his San Francisco lab, believing there will be a vaccine out by next year.
Earnings Update: Here’s Why Analysts Just Lifted Their Vaxart, Inc. (NASDAQ:VXRT) Price Target To US$6.50
Earnings Update: Here’s Why Analysts Just Lifted Their Vaxart, Inc. (NASDAQ:VXRT) Price Target To US$6.50
As you might know, Vaxart, Inc. (NASDAQ:VXRT) just kicked off its latest first-quarter results with some very strong...
simplywall.st
Vaxart and Emergent BioSolutions
May 18, 2020
0
Share
https://www.facebook.com/sharer.php...-candidates/vaxart-and-emergent-biosolutions/
https://twitter.com/intent/tweet?te.../vaxart-and-emergent-biosolutions/&via=GENbio
https://www.linkedin.com/shareArtic...tions/&title=Vaxart+and+Emergent+BioSolutions
https://reddit.com/submit?url=https...tions/&title=Vaxart+and+Emergent+BioSolutions
Candidates: Five vaccines based on proprietary VAAST™ Platform
Category: VAX
Type: Oral recombinant vaccines administered by room temperature-stable tablet
Status: Vaxart on April 30 said it obtained positive preclinical results for its COVID-19 vaccine candidates, with “several” of the candidates generating immune responses in all tested animals after a single dose. “These preclinical results confirm that all constructs are immunogenic as measured by IgG antibodies in serum, and we observed a robust boosting effect after the second dose,” Vaxart Chief Scientific Officer Sean Tucker, PhD, stated.
Tucker said Vaxart will use the data to select a lead candidate for manufacturing: “We remain on track to start a first phase 1 study in the second half of this year.”
Earlier in April, Vaxart reported positive preclinical results for its five COVID-19 vaccine candidates, saying that several of them generated immune responses in all tested animals after a single dose. Additional data will determine which of the candidates Vaxart advances into clinical trials, Chief Scientific Officer Sean Tucker, PhD, stated, adding: “We are particularly interested in vaccine candidates that can generate mucosal immune responses in addition to serum antibody responses.”
In March, Vaxart disclosed it had produced five COVID-19 vaccine candidates for testing in preclinical models. Each vaccine construct is based on a different coronavirus antigen combination, Vaxart said, adding that it expects to advance the best performing vaccine to manufacturing for clinical trials.
Vaxart has agreed to use the “molecule-to-market” contract development and manufacturing (CDMO) services of Emergent BioSolutions in preparation for cGMP production of a vaccine. Provided Vaxart elects to proceed with cGMP manufacturing, Emergent is expected to produce bulk cGMP vaccine for use in a Phase I study that Vaxart said could be launched in the second half of 2020. Vaxart also said it was prioritizing development of the COVID-19 vaccine by putting several vaccine programs on hold, including its therapeutic HPV vaccine program and a norovirus vaccine program for which the company completed a successful Phase I study, and was actively seeking a development partner.
Emergent has said it will provide development services out of its Gaithersburg, MD location and manufacture drug substance at its Bayview facility in Baltimore, designated a Center for Innovation in Advanced Development and Manufacturing (CIADM) by the U.S. Department of Health and Human Services.
Vaxart disclosed plans in January to generate vaccine candidates based on the published genome of SARS-CoV-2, and evaluate them in preclinical models based on their ability to generate both mucosal and systemic immune responses. The company cited a study published in The Lancet Infectious Diseases, showing that the Vaxart oral H1 influenza tablet vaccine primarily protected against infection based on mucosal immunity, compared with the injectable flu vaccine that protected primarily through systemic immunity.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
Vaxart, Emergent BioSolutions, and Kindred Biosciences - VXA-CoV2-1
Candidate: VXA-CoV2-1 Category: VAX Type: Oral recombinant vaccine administered by room temperature-stable tablet, and based on proprietary VAAST™ Platform. The vaccine is designed to target both the spike protein (S) and nucleoprotein (N). 2021 Status: Vaxart said February 25 that it will...
www.genengnews.com
Analysys Technical. Strong Buy
Análisis técnico de Vaxart (VXRT) - Investing.com
Acceda al análisis técnico de Vaxart, un resumen de las señales de compra/venta de los principales indicadores para las acciones de Vaxart (VXRT).
es.investing.com
Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate
Email Print Friendly Share
May 20, 2020 08:00 ET | Source: Vaxart, Inc.
Email Print Friendly Share
May 20, 2020 08:00 ET | Source: Vaxart, Inc.
KindredBio Selected as Second Contract Manufacturing Organization
GMP Production for Phase 1 Study Initiated
www.globenewswire.com
GMP Production for Phase 1 Study Initiated
Vaxart Announces Selection of its Oral COVID-19 Vaccine Lead Candidate
KindredBio Selected as Second Contract Manufacturing Organization GMP Production for Phase 1 Study Initiated SOUTH SAN FRANCISCO, Calif., May 20, 2020 ...
Moderna Starts a Phase 2 Clinical Trial for Its COVID-19 Vaccine
The vaccine is advancing through clinical trials at lightning speed.
Brian Orelli
(TMFBiologyFool)
Jun 1, 2020 at 8:53AM
Author Bio
finance.yahoo.com
The vaccine is advancing through clinical trials at lightning speed.
Brian Orelli
(TMFBiologyFool)
Jun 1, 2020 at 8:53AM
Author Bio
Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo Finance
Find the latest Moderna, Inc. (MRNA) stock quote, history, news and other vital information to help you with your stock trading and investing.
finance.yahoo.com
Similar threads
